This bill tightens rules for drug compounding pharmacies. It limits how often they can make near-copies of approved drugs, requires reports when they often send those drugs across state lines, and increases inspections and registration for large outsourcing facilities. It also lets federal officials raise facility fees to support safety work. This could reduce unsafe or misleading drugs, but may also limit access or raise costs for some custom medicines.
